Skip to main content
. 2009 May 20;83(15):7706–7717. doi: 10.1128/JVI.00683-09

FIG. 1.

FIG. 1.

Chemical structure and antiviral activity of the INI GSK501015. (A) Structure of the two-metal-binding naphthyridinone derivative GSK501015. (B to E) Dose-response curves for the antiviral potency of the INI GSK501015 in ex vivo cultures of primary T cells and macrophages from hCD4/hCCR5 transgenic rats and humans. (B and C) Activated T cells from both species. (D) Spleen-derived macrophages from double-transgenic rats. (E) Monocyte-derived macrophages from human donors were pretreated with the INI and subsequently challenged with HIV-1R7/3 YU-2 Env GFP (T cells) or VSV-G HIV-1NL4-3 GFP (macrophages). On day 3 postinfection, the percentage of GFP-positive cells was scored by flow cytometry, and the values obtained for untreated controls were set to 100%. Given are arithmetic means ± standard deviations (n = 3) of one experiment. EC50s were determined by using Prism software (GraphPad, San Diego, CA) and are shown in panels B to E and in Table 3.